Experimental DMD drug shows promise in small early trial
Disease control
Terminated
This study tested a new drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be fixed by skipping a part of their DNA called exon 51. The main goal was to see if the drug is safe and tolerable when given through a vein over several months,…
Phase: PHASE2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated May 15, 2026 11:55 UTC